drugset / Trial / NCT05755581
Efficacy of Neoadjuvant Endocrine Therapy Compared to Chemotherapy in Breast Cancer Patients
RandomizedParallel-groupOpen-labelBasic science
Summary
Eligible patients will be divided into two groups; one will receive neoadjuvant endocrine therapy and the other one will receive neoadjuvant chemotherapy.
Timeline
- Start
- 2023-04-01
- Primary completion
- 2025-04-01
- Completion
- 2025-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Goserelin | Other / unclassified | 3.6 mg | — |
| Comparator | Tamoxifen | Small molecule | 20 mg | — |